- Home
- ACON vs OGEN Comparison
ACON vs OGEN Comparison
Compare ACON & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACON | OGEN |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 3.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACON | OGEN |
|---|---|---|
| Price | $3.42 | $0.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 908.6K |
| Earning Date | 11-12-2025 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,483.00 | N/A |
| Revenue This Year | $71.77 | N/A |
| Revenue Next Year | $80.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.91 | N/A |
| 52 Week Low | $3.28 | $0.74 |
| 52 Week High | $562.68 | $18.90 |
Technical Indicators
Market Signals| Indicator | ACON | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 44.95 |
| Support Level | $3.68 | $0.77 |
| Resistance Level | $3.75 | $0.85 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 0.00 | 25.91 |
Price Performance
Historical ComparisonAbout ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.